177Lu-PSMA Radioligand Therapy for Prostate Cancer
暂无分享,去创建一个
[1] A. Seth,et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Rolf Fimmers,et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[3] W. Weichert,et al. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.
[4] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.
[5] G. Feldmann,et al. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[6] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[7] W. Brenner,et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, The Journal of Nuclear Medicine.
[8] K. Herrmann,et al. From NETTER to PETTER: PSMA-Targeted Radioligand Therapy , 2017, The Journal of Nuclear Medicine.
[9] P. Carroll,et al. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience , 2017, The Journal of Nuclear Medicine.
[10] R. Baum,et al. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013 , 2016, The Journal of Nuclear Medicine.
[11] Oliver Sartor,et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Böning,et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer , 2016, Oncotarget.
[13] U. Haberkorn,et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.
[14] M. Schwaiger,et al. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. , 2016, The Journal of urology.
[15] F. Mottaghy,et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[16] K. Rahbar,et al. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer , 2016, Clinical nuclear medicine.
[17] M. Schwaiger,et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[18] M. Schwaiger,et al. Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[19] K. Rahbar,et al. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis , 2016, The Journal of Nuclear Medicine.
[20] A. Drzezga,et al. Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617 , 2016, Molecular Imaging and Biology.
[21] R. Fimmers,et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer , 2016, Oncotarget.
[22] R. Baum,et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.
[23] Michael Lassmann,et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies , 2015, The Journal of Nuclear Medicine.
[24] E. Demirci,et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[25] U. Haberkorn,et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[26] W. Olson,et al. Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer , 2015, The Prostate.
[27] U. Haberkorn,et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[28] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[29] M. Cremonesi,et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[30] U. Haberkorn,et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.
[31] A. Haese*,et al. High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.
[32] H. Ananias,et al. Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer , 2009, The Prostate.
[33] Slave Trajanoski,et al. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.
[34] J. Seidel,et al. N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer , 2008, Clinical Cancer Research.
[35] Matthias D Hofer,et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.
[36] Prabhjot Kaur,et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] J. Bowie,et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. , 2003, Molecular biology of the cell.
[38] William C. Olson,et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] E. Woltering,et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. , 2002, Seminars in nuclear medicine.
[40] J. Neale,et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). , 2001, Journal of medicinal chemistry.
[41] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[42] Kratochwil Clemens,et al. Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Dosimetry estimate and empirical dose finding , 2017 .
[43] K. Rahbar,et al. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. , 2016, Nuklearmedizin. Nuclear medicine.
[44] U. Haberkorn,et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[45] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.
[46] Thomas Wiegel,et al. Guidelines on Prostate Cancer , 2013 .
[47] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.